, Tracking Stock Market Picks
Enter Symbol:
Avanir Pharmaceuticals (AVNR) [hlAlert]

up 493.00 %

Avanir Pharmaceuticals (AVNR) rated Buy with price target $6 by MLV & Co

Posted on: Friday,  Jan 20, 2012  8:25 AM ET by MLV & Co

MLV & Co rated Buy Avanir Pharmaceuticals (NASDAQ: AVNR) on 01/20/2012, when the stock price was $2.86. Since
then, Avanir Pharmaceuticals has gained 493.01% as of 01/12/2015's recent price of $16.96.
If you would have followed this MLV & Co's recommendation on AVNR, you would have gained 493% of your investment in 1088 days.

Avanir Pharmaceuticals is a pharmaceutical company focused on developing, acquiring and commercializing therapeutic products for the treatment of chronic diseases. The Company?s product candidates address therapeutic markets that include the central nervous system and inflammatory diseases. Its principal product candidate, Zenviatm (dextromethorphan hydrobromide/quinidine sulfate), is in Phase III clinical development for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic pain (DPN pain). The Company?s first commercialized product, docosanol 10% cream, (sold as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare in North America) is an over-the-counter treatment for cold sores that has been approved by the United States Food and Drug Administration (FDA).

MLV & Co is a boutique investment bank and institutional broker-dealer focused on providing independent financial advice and unique capital markets expertise to corporate and institutional clients in capital intensive industries such as metals and mining, life sciences, energy and real estate. With a focus on raising money efficiently for clients, MLV has rapidly become a leader in the At-the-Market(ATM) transaction market.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/20/2012 8:25 AM Buy
2.86 6.00
as of 12/31/2012
1 Week down  -0.38 %
1 Month down  -0.75 %
3 Months down  -18.12 %
1 YTD down  -8.39 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy